These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 18923406)

  • 21. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.
    Lai-Goldman M; Faruki H
    Genet Med; 2008 Dec; 10(12):874-8. PubMed ID: 19092439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving drug safety by locating genetic markers for hypersensitivity reactions.
    Ronaldson KJ; McNeil JJ
    Med J Aust; 2009 Jun; 190(11):641-3. PubMed ID: 19485844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epilepsy pharmacogenetics : science or fiction?].
    Depondt C
    Med Sci (Paris); 2013 Feb; 29(2):189-93. PubMed ID: 23452606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.
    Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A
    Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.
    Stingl Kirchheiner JC; Brockmöller J
    Clin Pharmacol Ther; 2011 Feb; 89(2):198-209. PubMed ID: 21209614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
    Alfirevic A; Pirmohamed M
    Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA and pharmacogenetics of drug hypersensitivity.
    Pavlos R; Mallal S; Phillips E
    Pharmacogenomics; 2012 Aug; 13(11):1285-306. PubMed ID: 22920398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
    Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
    Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine].
    Mushiroda T
    Rinsho Byori; 2013 May; 61(5):422-7. PubMed ID: 23947182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA and drug-induced toxicity.
    Phillips EJ; Mallal SA
    Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.